News
-
Shenox receives allowances for the first patent for SHX-001, a transdermal delivery system for ketamine, from Japan, South Korean, Australia, Canada and the U.S. in March 2022
Shenox is pleased to announce that allowances for the first patent for a transdermal delivery system for ketamine have been received from multiple countries including Japan, South Korean, Australia, C
-
Progress of SHX-001
Shenox completed a phase 2b preparation meeting with the FDA and has reached agreements on nonclinical requirements and overall clinical design.
-
SHX-001 completed the first patient administration of FIH
On January 21, 2019, Shenox completed the administration of first MDD patient in the SHX-001 First in Human trial at the Maryland site in US.
